NCT02635672
Who may be able to join
Who might be able to join this trial:
- You are 18 years old or older
- You have a solid tumor or an aggressive type of blood cancer called NHL that has been confirmed by lab testing, and your cancer either has not responded to or you have already tried all available treatments, and your cancer shows a specific genetic feature called MYC expression or C-MYC changes
- Your bone marrow, liver, and kidneys are working well enough (as measured by blood tests)
- You are reasonably able to carry out daily activities, rated on a standard scale from fully active to capable of limited self-care (confirm with trial site)
- (For certain parts of the trial in the US only) You meet the requirements to safely receive a medicine called pembrolizumab, based on official prescribing guidelines
Who may not be able to join:
- You currently have a serious active infection
- You have cancer that has recently spread to, or is getting worse in, the brain, the lining of the brain, or the spinal cord
- You have received chemotherapy or immunotherapy during the study or within 1 week before starting the trial treatment
- You have had major surgery or a serious injury within the 4 weeks before starting the trial treatment
- You have had a bone marrow or stem cell transplant from another person within 4 months before starting the trial, or you are still taking medicines to suppress your immune system after such a transplant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of DLT (Dose limit toxicity) of VIP152 (BAY1251152); Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of VIP152 (BAY1251152); Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP152 (BAY1251152); AUC from time 0 to the last data point > Lower limit of quantitation (LLOQ) [AUC(0-tlast)] of VIP152 (BAY1251152); Maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval (Cmax,md) of VIP152 (BAY1251152); AUC from time 0 to the last d...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.